Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patientsâ lives. Aptevo has a commercial product, IXINITYÂŽ coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology â the ADAPTIR⢠modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source
No articles found.
Quidel Corporation (Nasdaq: QDEL) is a California-based leading manufacturer of di...
Quidel Corporation (Nasdaq: QDEL) is a Californ...
Neurocarrus is developing a breakthrough therapy ( N-001 ) to fulfill the unmet ne...
Neurocarrus is developing a breakthrough therap...
Viemed Healthcare Inc is a high level service provider using best in class technol...
Viemed Healthcare Inc is a high level service p...
Neopenda is a medical device startup creating solutions that give patients in low-...
Neopenda is a medical device startup creating s...
As a leading provider of innovative technologies for the treatment of Atrial Fibri...
As a leading provider of innovative technologie...
Aviana Molecular Technologies, LLC (Aviana) is an Orlando, FL based point of care ...
Aviana Molecular Technologies, LLC (Aviana) is ...
Hutchison China MediTech Limited, known as Chi-Med, is an innovative biopharmaceut...
Hutchison China MediTech Limited, known as Chi-...
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing ...
Trillium Therapeutics Inc. is a clinical stage ...
Vaccinex is a clinical-stage biotechnology company engaged in the discovery and de...
Vaccinex is a clinical-stage biotechnology comp...
Surface Oncology is an immuno-oncology company on a mission to break through and d...
Surface Oncology is an immuno-oncology company ...
Join the National Investor Network and get the latest information with your interests in mind.